[go: up one dir, main page]

NO812612L - Enzym-inhibitorer. - Google Patents

Enzym-inhibitorer.

Info

Publication number
NO812612L
NO812612L NO812612A NO812612A NO812612L NO 812612 L NO812612 L NO 812612L NO 812612 A NO812612 A NO 812612A NO 812612 A NO812612 A NO 812612A NO 812612 L NO812612 L NO 812612L
Authority
NO
Norway
Prior art keywords
phe
leu
pro
val
protected
Prior art date
Application number
NO812612A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Szelke
David Michael Jones
Allan Hallett
Original Assignee
Ferring Pharma Ltd
Ferring Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Pharma Ltd, Ferring Ab filed Critical Ferring Pharma Ltd
Publication of NO812612L publication Critical patent/NO812612L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/86—Renin inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO812612A 1980-08-06 1981-07-31 Enzym-inhibitorer. NO812612L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8025579 1980-08-06
GB8118194 1981-06-12

Publications (1)

Publication Number Publication Date
NO812612L true NO812612L (no) 1982-02-08

Family

ID=26276457

Family Applications (1)

Application Number Title Priority Date Filing Date
NO812612A NO812612L (no) 1980-08-06 1981-07-31 Enzym-inhibitorer.

Country Status (9)

Country Link
US (1) US4424207A (sv)
EP (1) EP0045665B1 (sv)
AU (1) AU549157B2 (sv)
DE (1) DE3172138D1 (sv)
DK (1) DK349481A (sv)
ES (1) ES8305306A1 (sv)
FI (1) FI812427A7 (sv)
IE (1) IE51471B1 (sv)
NO (1) NO812612L (sv)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609643A (en) * 1980-08-06 1986-09-02 Aktiebolaget Hassle Renin inhibitors, treatments and dipeptide synthesis
EP0104041B1 (en) * 1982-09-15 1988-07-27 Aktiebolaget Hässle Enzyme inhibitors
US4650661A (en) * 1982-09-15 1987-03-17 Aktiebolaget Hassle Enzyme inhibitors
US4595677A (en) * 1982-12-03 1986-06-17 Ciba-Geigy Corporation Substituted tetrapeptides
GB2135773B (en) * 1983-01-31 1985-12-04 Boots Celltech Diagnostics Enzyme inhibitor labelled immunoassay
GB8322414D0 (en) * 1983-08-19 1983-09-21 Szelke M Renin inhibitors
FI843837L (fi) * 1983-02-07 1984-09-28 Ferring Ab Enzyminhibitorer.
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
IT1164239B (it) * 1983-05-25 1987-04-08 Anic Spa Un retro-inverso analogo del decapeptide (5-14)dell'angiotensinogeno equino inibitore specifico della renina con elevata resistenza all'idrolisi enzimatica
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
EP0144290A3 (de) * 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituierte Aethylendiaminderivate
JPS60163899A (ja) * 1984-02-03 1985-08-26 Sankyo Co Ltd レニン阻害ペプチド類
FI850948A7 (sv) * 1984-03-12 1985-09-13 Pfizer Renin inhibitorer som innehåller statin eller dess derivat.
US4668663A (en) * 1984-03-27 1987-05-26 Merck & Co., Inc. Renin inhibitors containing homophe8
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
EP0156318A3 (en) * 1984-03-27 1988-07-06 Merck & Co. Inc. C-terminal amide cyclic renin inhibitors containing peptide isosteres
US4663310A (en) * 1984-04-04 1987-05-05 Merck & Co., Inc. Renin inhibitors containing 2-substituted statine
EP0163237A3 (en) * 1984-05-29 1988-04-27 Merck & Co. Inc. Di- and tri-peptidal renin inhibitors
US4652551A (en) * 1984-06-22 1987-03-24 Abbott Laboratories Renin inhibiting compounds
US4645759A (en) * 1984-06-22 1987-02-24 Abbott Laboratories Renin inhibiting compounds
US4880781A (en) * 1984-08-06 1989-11-14 The Upjohn Company Renin inhibitory peptides containing an N-alkyl-histidine moiety
FI88400C (sv) * 1984-08-06 1993-05-10 Upjohn Co Förfarande för framställning av renin inhiberande peptider
DE3438545A1 (de) * 1984-10-20 1986-04-24 Merck Patent Gmbh, 6100 Darmstadt Peptide
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4727060A (en) * 1984-11-13 1988-02-23 Ciba-Geigy Corporation Novel 5-amino-4-hydroxyvaleryl derivatives
DE3512128A1 (de) 1985-04-03 1986-10-09 Merck Patent Gmbh, 6100 Darmstadt Peptide
US4882420A (en) * 1985-04-19 1989-11-21 The Upjohn Company Dihalo-statine substituted renin inhibitors
FI865196L (fi) 1985-04-19 1986-12-18 Upjohn Co Halostatinsubstituerade renin-inhibitorer.
US4826815A (en) * 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
US4665055A (en) * 1985-06-17 1987-05-12 Merck & Co., Inc. Peptide renin inhibitors
US4777286A (en) * 1985-06-18 1988-10-11 The Upjohn Company Certain aryl or hetero-hydroxamic acid esters useful as renin inhibitors
US4992562A (en) * 1985-08-09 1991-02-12 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
US4729985A (en) 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
US4906613A (en) * 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
DE3540495A1 (de) * 1985-11-15 1987-05-21 Merck Patent Gmbh Aminosaeurederivate
US4894437A (en) * 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
WO1987004349A1 (en) * 1986-01-16 1987-07-30 Joseph Dellaria Peptide analogs
FI870474A7 (fi) * 1986-02-07 1987-08-08 Ciba Geigy Ag Med svavelhaltiga grupper substituerade 5-amino-4-hydroxivalerylderivat.
CA1309555C (en) * 1986-02-27 1992-10-27 Suvit Thaisrivongs Inhibiting peptides having a dihydroxyethylene isostere transitionstate insert
US4705846A (en) * 1986-03-27 1987-11-10 The Upjohn Company Novel renin inhibiting peptides having a gamma lactam pseudo dipeptide insert
US4743584A (en) * 1986-10-07 1988-05-10 Merck & Co., Inc. C-terminal amide cyclic renin inhibitors containing peptide isosteres
EP0264106B1 (en) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US4743585A (en) * 1986-11-21 1988-05-10 Warner-Lambert Company Renin inhibitors
US4758584A (en) * 1987-02-05 1988-07-19 Ciba-Geigy Corporation Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups
US5162497A (en) * 1987-09-24 1992-11-10 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
ES2058489T3 (es) * 1988-01-26 1994-11-01 Sankyo Co Oligopeptidos con actividades inhibidoras de la renina, su preparacion y su uso.
WO1989009230A1 (en) * 1988-03-25 1989-10-05 Administrators Of The Tulane Educational Fund Therapeutic peptides
IL90872A0 (en) * 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
US5688770A (en) * 1989-12-14 1997-11-18 Schering Corporation Antiglaucoma compositions and methods
US5869615A (en) * 1994-01-03 1999-02-09 Washington University Modified complement proteases
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6239273B1 (en) 1995-02-27 2001-05-29 Affymetrix, Inc. Printing molecular library arrays
US6046169A (en) * 1995-06-07 2000-04-04 Cor Therapeutics, Inc. Inhibitors of factor XA
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
KR100436680B1 (ko) 1995-06-07 2004-09-18 글락소 그룹 리미티드 트롬보포이에틴 수용체에 결합하는 펩티드 및 화합물
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5919765A (en) * 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6245743B1 (en) 1996-06-05 2001-06-12 Cor Therapeutics, Inc. Inhibitors of factor Xa
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
AU2610000A (en) 1999-01-12 2000-08-01 Cambridge University Technical Services Limited Compounds and methods to inhibit or augment an inflammatory response
US6682739B1 (en) 1999-07-28 2004-01-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US7041465B1 (en) 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
US6808710B1 (en) 1999-08-23 2004-10-26 Genetics Institute, Inc. Downmodulating an immune response with multivalent antibodies to PD-1
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
AU2002338272B2 (en) 2001-04-02 2007-10-11 Dana-Farber Cancer Institute, Inc. PD-1, a receptor for B7-4, and uses therefor
JP2005532263A (ja) 2002-02-06 2005-10-27 ヴァイコー テクノロジーズ， インコーポレイテッド 抗梗塞分子
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004111192A2 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20100330143A1 (en) 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
ZA200604869B (en) 2003-12-04 2007-11-28 Univ Utah Res Found Modified macromolecules and methods of making and using thereof
JP2007526000A (ja) 2004-03-04 2007-09-13 バンダービルト ユニバーシティ サイトカイン誘導性シグナル伝達を阻害する細胞透過性ｓｏｃｓポリペプチド
CA2566703A1 (en) 2004-05-11 2005-11-24 Vishwa Deep Dixit Methods of inhibiting proinflammatory cytokine expression using ghrelin
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
JP5243040B2 (ja) 2004-12-21 2013-07-24 ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント 創傷治癒および組織再生を促進するための組成物および方法
US8158586B2 (en) 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
KR20080007491A (ko) 2005-04-29 2008-01-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
WO2006127020A1 (en) 2005-05-19 2006-11-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
ES2451667T3 (es) 2005-06-07 2014-03-28 Ocean Nutrition Canada Limited Microorganismos eucariotas para producir lípidos y antioxidantes
CA2605832C (en) 2005-06-16 2018-05-08 Ocean Nutrition Canada Ltd. Immobilized enzymes and methods of using thereof
AU2006278264B2 (en) 2005-08-05 2012-12-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
CA2659958A1 (en) 2005-08-05 2007-02-15 Pharmagap Inc. Peptides targeted to protein kinase c isoforms and uses thereof
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
JP5178520B2 (ja) 2005-09-22 2013-04-10 メディバス エルエルシー 固体ポリマー送達組成物およびその使用法
CA2625183C (en) 2005-10-04 2019-09-03 Inimex Pharmaceuticals Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
EP2395076A1 (en) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
ZA200804082B (en) 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
US20070190543A1 (en) 2005-11-14 2007-08-16 Applera Corporation Coded Molecules for Detecting Target Analytes
WO2007056867A1 (en) 2005-11-21 2007-05-24 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8993719B2 (en) 2005-12-29 2015-03-31 The Regents Of The University Of California Methods and compositions related to mutant Kunitz domain I of TFPI-2
WO2007092447A2 (en) 2006-02-06 2007-08-16 Burnham Institute For Medical Research Methods and compositions related to targeting tumors and wounds
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US8865398B2 (en) 2006-09-01 2014-10-21 Abbott Laboratories Combination hepatitis C virus antigen and antibody detection method
US20100190689A1 (en) 2006-09-21 2010-07-29 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
US8637459B2 (en) 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
US9101671B2 (en) 2007-01-03 2015-08-11 Sanford-Burnham Medical Research Institute Methods and compositions related to clot binding compounds
WO2008089440A2 (en) 2007-01-18 2008-07-24 University Of Utah Research Foundation Compositions and methods for detecting, treating, or preventing reductive stress
WO2008121437A2 (en) 2007-02-08 2008-10-09 The Burnham Institute For Medical Research Trophinin-binding peptides and uses thereof
CA2677665C (en) 2007-02-08 2019-11-05 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2155894A4 (en) 2007-05-09 2010-08-18 Burnham Inst Medical Research HOST PROTEINAS AS A TARGET FOR A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL DISEASES
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
KR20190085187A (ko) 2008-01-22 2019-07-17 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
CA2713872A1 (en) 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
US8841440B2 (en) 2008-04-01 2014-09-23 Cornell University Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof
DK2297307T3 (en) 2008-06-04 2016-07-25 Cellular Dynamics Int Inc PROCEDURES FOR THE MANUFACTURE OF IPS CELLS USING NON-VIRAL METHODS
EP2310035B1 (en) 2008-06-16 2015-08-26 University Of Rochester Fibroblast growth factor (fgf) analogs and uses thereof
WO2010019120A1 (en) 2008-08-15 2010-02-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
EP2939683B1 (en) 2009-02-16 2017-01-04 Cerenis Therapeutics Holding SA Apolipoprotein A-I Mimics
EP3150701B1 (en) 2009-06-05 2018-10-03 FUJIFILM Cellular Dynamics, Inc. Reprogramming t cells and hematopoietic cells
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US8409603B2 (en) 2009-10-01 2013-04-02 University Of South Carolina Compositions and methods for tissue engineering, tissue regeneration and wound healing
CA2779846A1 (en) 2009-11-04 2011-05-12 Novartis Ag Positively charged species as binding reagents in the separation of protein aggregates from monomers
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US8968740B2 (en) 2009-11-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
EP2512497A1 (en) 2009-12-18 2012-10-24 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
IT1397901B1 (it) 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
WO2011127405A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
US20140323392A1 (en) 2011-03-28 2014-10-30 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
AU2012262488A1 (en) 2011-05-31 2014-01-16 Airware, Inc. Re-calibration of AB NDIR gas sensors
CA2838188C (en) 2011-06-04 2017-04-18 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
AU2013211929B2 (en) 2012-01-26 2016-05-26 Christopher J. Soares Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use
WO2013130808A1 (en) 2012-02-29 2013-09-06 D.E. Shaw Research, Llc Methods for screening voltage gated proteins
WO2013154771A1 (en) 2012-04-12 2013-10-17 Georgia Regents University Redox-resistant nitric oxide synthase
WO2013162748A1 (en) 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2013192504A1 (en) 2012-06-22 2013-12-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
EP3613765B1 (en) 2012-08-03 2024-10-02 Dana-Farber Cancer Institute, Inc. Antibody against repulsive guidance molecule b (rgmb)
EP2892558B1 (en) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
AU2014239186B2 (en) 2013-03-14 2017-04-20 Lipimetix Development, Llc Apolipoprotein mimetics and uses thereof
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
EP3027225B1 (en) 2013-07-31 2021-03-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using transforming growth factor alpha
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CN106661107B (zh) 2013-12-24 2021-12-24 杨森制药公司 抗vista抗体及片段
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
CN113967258B (zh) 2014-06-13 2024-07-02 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
JP6810690B2 (ja) 2014-08-06 2021-01-13 ヴァスキュラー バイオサイエンスィズVascular Biosciences 疾患組織に対する選択性を有するファルマコフォアを含む組成物およびその生成方法
WO2016049380A1 (en) 2014-09-24 2016-03-31 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
EP3229837B1 (en) 2014-12-08 2025-02-05 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
WO2017040350A1 (en) 2015-08-28 2017-03-09 Navigen, Inc Compositions and methods related to inhibition of respiratory syncytial virus entry
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017083700A1 (en) 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
EP3413910A1 (en) 2016-02-12 2018-12-19 Janssen Pharmaceutica NV Anti-vista (b7h5) antibodies
CN115010808A (zh) 2016-03-16 2022-09-06 阿贝奥姆公司 针对il-25的中和单克隆抗体及其用途
CN109641037B (zh) 2016-04-13 2022-09-06 西安奥瑞单抗生物技术有限公司 抗psma抗体及其用途
IL322448A (en) 2016-04-15 2025-09-01 Immunext Inc Humanized anti-vista antibodies and their use
WO2018045083A1 (en) 2016-09-02 2018-03-08 Soares Christopher J Use of cgrp receptor antagonists in neuroprotection and neurological disorders
AU2017325839B2 (en) 2016-09-14 2024-11-14 The Trustees Of The University Of Pennsylvania Proximity-based sortase-mediated protein purification and ligation
EP3538131B1 (en) 2016-11-09 2025-05-07 Mayo Foundation for Medical Education and Research Manp analogues
UY37753A (es) 2017-06-02 2018-11-30 Amgen Inc Antagonistas de péptido pac1
US20210032334A1 (en) 2018-02-28 2021-02-04 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
MX2020010094A (es) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
MX2020012208A (es) 2018-05-16 2021-03-02 Res Institute At Nationwide Children´S Hospital Generacion de linfocitos cn humanos primarios y expandidos inactivados al usar ribonucleoproteínas cas9.
EP3802762B1 (en) 2018-06-05 2023-12-13 DSM IP Assets B.V. Process for the production of diglycerides
JP2022506716A (ja) 2018-11-09 2022-01-17 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 抵抗性高血圧に対する併用療法
WO2020256795A1 (en) 2019-06-19 2020-12-24 The Research Foundation For The State University Of New York Methods for treating neointimal hyperplasia using f11r/jam-a inhibitors
EP4093513A4 (en) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2025054172A1 (en) 2023-09-05 2025-03-13 E-Star Biotech, LLC Formulations of manp and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1585061A (en) * 1977-03-15 1981-02-25 Nat Res Dev Synthesis of peptides
US4198398A (en) 1977-07-12 1980-04-15 Derek Hudson Enkephalin analogues

Also Published As

Publication number Publication date
ES504575A0 (es) 1983-04-01
IE811785L (en) 1982-02-06
FI812427L (fi) 1982-02-07
US4424207A (en) 1984-01-03
EP0045665B1 (en) 1985-09-04
AU549157B2 (en) 1986-01-16
ES8305306A1 (es) 1983-04-01
FI812427A7 (sv) 1982-02-07
DE3172138D1 (en) 1985-10-10
IE51471B1 (en) 1986-12-24
DK349481A (da) 1982-02-07
AU7381581A (en) 1982-02-11
EP0045665A1 (en) 1982-02-10

Similar Documents

Publication Publication Date Title
NO812612L (no) Enzym-inhibitorer.
EP0118223A1 (en) Enzyme inhibitors
US4485099A (en) Renin inhibitors containing a C-terminal amide cycle
US4261886A (en) Peptides having thymopoietin-like activity
CA2325572A1 (en) Process for the preparation of resin-bound cyclic peptides
US4713445A (en) Renin inhibitors and treatments using them
US4609643A (en) Renin inhibitors, treatments and dipeptide synthesis
KR910001724B1 (ko) 향정신성 펩티드류의 제조방법
USRE30731E (en) Enkephalin analogues
KR930004056B1 (ko) 신규한 펩티드
AU623131B2 (en) Tyr-peptide analogs
EP0127234B1 (en) A retro-inverso analogue of the (5-14) decapeptide of equine angiotensinogen, as a specific renin inhibitor with high resistance to enzymatic hydrolysis
US5508437A (en) Analogs of tyrosine sulfate or tyrosine phosphate containing peptides
US6673769B2 (en) Lanthionine bridged peptides
US4496543A (en) Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
CN102120727A (zh) N-[(3s)-n-氨基酰-1，2，3，4-四氢异喹啉-3-甲酰基]氨基酸及其合成方法和应用
US4716149A (en) Partially modified, retro-inverso neurotensin analogs
CA1249396A (en) Partially retro-inverted decapeptide as a specific renin inhibitor with high resistance to enzymatic hydrolysis
JPH01199997A (ja) 哺乳動物の脳下垂体に作用するペプチド
NO148070B (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive angiotensin ii analoger
RU2010799C1 (ru) Производные пентапептидов
JPS61155395A (ja) ｒｅｔｒｏ逆転ペプチド及びその合成法
JPS6143199A (ja) １‐，５‐，及び８‐位置で置換されるアンギオテンシン‐２類似体の製造方法
JPH04295496A (ja) インスリン活性を有する短ペプチド
UCHIYAMA et al. Studies on Secretin. I. Synthesis of Completely Protected Secretin